Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 74

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 74
---
 INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

NOTE 17—CONTINGENT CONSIDERATION GAINS, RESTRUCTURING CHARGES AND OTHER

Contingent consideration gains, restructuring charges and other for the years ended December 31, 2024, 2023 and 2022 are summarized below (in thousands):Year Ended December 31,202420232022Contingent consideration gains:Flexion contingent consideration$(4,457)$(3,424)$(18,292)MyoScience contingent consideration— — (11,184)Total contingent consideration gains(4,457)(3,424)(29,476)Acquisition-related charges:Acquisition-related expenses1,462 1,963 1,032 Severance-related expenses— — 4,494 Other acquisition expenses— — 5,719 Total acquisition-related charges1,462 1,963 11,245 Restructuring charges8,532 1,109 — Loss on lease termination2,165 — — Impairment of acquired IPR&D— — 26,134 Termination of license agreement— — 3,000 Total contingent consideration gains, restructuring charges and other$7,702 $(352)$10,903 Flexion Acquisition Contingent ConsiderationFor the years ended December 31, 2024, 2023 and 2022 the Company recognized contingent consideration gains of $4.5 million, $3.4 million and $18.3 million, respectively, due to a decrease in the fair value of its contingent consideration related to the Flexion Acquisition. See Note 11, Financial Instruments, for information regarding the method and key assumptions used in the fair value measurements of the Company’s contingent consideration and more information regarding the changes in fair value.MyoScience Acquisition Contingent ConsiderationThe Company recognized contingent consideration gains related to the MyoScience Acquisition of $11.2 million for the year ended December 31, 2022. See Note 11, Financial Instruments, for information regarding the method and the changes in fair value.Acquisition-Related ChargesThe Company recognized acquisition-related charges of $1.5 million and $2.0 million during the years ended December 31, 2024 and 2023 primarily related to vacant and underutilized Flexion leases that were assumed from the Flexion Acquisition.